InnoCare Pharma Ltd. Statistics
Want to see HK:9969 full AI Analyst Report?
InnoCare Pharma Ltd. (9969) Stock Statistics & Valuation Metrics
Total Valuation
InnoCare Pharma Ltd. has a market cap or net worth of HKD 18.01B. The enterprise value is HKD 21.04B.
- Market Cap
- HKD 18.01B
- Enterprise Value
- HKD 21.04B
Share Statistics
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,496,284,200
- Owned by Insiders
- ―
- Owned by Institutions
- 7.72%
Financial Efficiency
InnoCare Pharma Ltd.’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 4.43%.
- Return on Equity (ROE)
- 0.08
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 4.43%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 1.66M
- Profits Per Employee
- 450.89K
- Employee Count
- 1,388
- Asset Turnover
- 0.21
- Inventory Turnover
- 1.75
Valuation Ratios
The current PE Ratio of InnoCare Pharma Ltd. is 13.17. InnoCare Pharma Ltd.’s PEG ratio is 0.02.
- PE Ratio
- 13.17
- PS Ratio
- 4.54
- PB Ratio
- 2.18
- Price to FCF
- 46.16
- Price to Operating Cash Flow
- 38.92
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, InnoCare Pharma Ltd. had revenue of 2.30B and earned 625.84M in profits. Earnings per share was 0.36.
- Revenue
- 2.30B
- Gross Profit
- 2.01B
- Operating Income
- 440.59M
- Pretax Income
- 638.77M
- Net Income
- 625.84M
- EBITDA
- 555.89M
- Earnings Per Share (EPS)
- 0.36
Cash Flow
In the last 12 months, operating cash flow was 459.76M and capital expenditures -132.10M, giving a free cash flow of 327.66M billion.
- Operating Cash Flow
- 459.76M
- Free Cash Flow
- 327.66M
- Free Cash Flow per Share
- 0.19
Dividends & Yields
InnoCare Pharma Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.17%
- Earnings Yield
- 7.55%
Stock Price Statistics
- Beta
- 1.18
- 52-Week Price Change
- -17.93%
- 50-Day Moving Average
- 13.44
- 200-Day Moving Average
- 13.12
- Relative Strength Index (RSI)
- 43.64
- Average Volume (3m)
- 7.79M
Important Dates
InnoCare Pharma Ltd. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 26, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
InnoCare Pharma Ltd. as a current ratio of 5.83, with Debt / Equity ratio of 20.85%
- Current Ratio
- 5.83
- Quick Ratio
- 5.71
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- -9.83
- Interest Coverage Ratio
- 8.21
Taxes
In the past 12 months, InnoCare Pharma Ltd. has paid 11.26M in taxes.
- Income Tax
- 11.26M
- Effective Tax Rate
- 0.02
Enterprise Valuation
InnoCare Pharma Ltd. EV to EBITDA ratio is 8.61, with an EV/FCF ratio of 34.77.
- EV to Sales
- 3.42
- EV to EBITDA
- 8.61
- EV to Free Cash Flow
- 34.77
- EV to Operating Cash Flow
- 24.78
Balance Sheet
InnoCare Pharma Ltd. has HKD 6.49B in cash and marketable securities with HKD 2.13B in debt, giving a net cash position of HKD 4.36B billion.
- Cash & Marketable Securities
- HKD 6.49B
- Total Debt
- HKD 2.13B
- Net Cash
- HKD 4.36B
- Net Cash Per Share
- HKD 2.91
- Tangible Book Value Per Share
- HKD 4.50
Margins
Gross margin is 91.09%, with operating margin of 37.27%, and net profit margin of 40.53%.
- Gross Margin
- 91.09%
- Operating Margin
- 37.27%
- Pretax Margin
- 41.04%
- Net Profit Margin
- 40.53%
- EBITDA Margin
- 39.71%
- EBIT Margin
- 36.84%
Analyst Forecast
The average price target for InnoCare Pharma Ltd. is HKD 19.07, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- HKD 19.07
- Price Target Upside
- 60.21% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 146.27%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 7
- AI Score
- 65
